More choice ingredients for the Vaccine Industry .. if you thought the ingredients of milk complete with the universal pus from mastitis and the the antibiotics was the worst that could be done .. the powers that be .. go to sell the blood from these diseased creatures for vaccines .. this to be injected into the blood stream of babies to cause further disease down the track in the human population.
One report states that this year 9000 tonnes of cows blood will be exported and will be expected to increase 6 fold over the next 5 years .. the Dairy Industry demonstrates all that is wrong with our Agricultural Policy .. Dairy has affected the ecology of the nation from the smallest organism to huge waterways and pollution on a massive scale.
This is a criminal act.
Silver Fern Farms is moving up the value chain with the announcement of a long-term blood protein joint partnership with a world-leading biotechnology company.‘Silver Fern Farms in deal with world-leading biotech company’
Silver Fern Farms is moving up the value chain with the announcement of a long-term blood protein joint partnership with a world-leading biotechnology company.
The partnership to produce bovine blood plasma products is with US-based company Proliant Inc., an innovator in applied protein sciences for food, health and nutrition.
Proliant is the world’s leading producer of bovine serum albumin (BSA) which is used in the production of diagnostic/medical kit manufacturing, biopharmaceuticals, veterinary medicines, vaccines and antibodies, nutraceuticals and life-science research.
Keith Cooper, Silver Fern Farms’ Chief Executive, says the agreement fits with the company’s strategy of creating value from co-products and with the company’s sustainability ethos.
“Proliant is an ideal partner, offering high technology, processing and global marketing expertise. A partnership of this nature, with the potential for additional multi-million dollar revenue to our co-operative over the tenure of the agreement will ensure that together we make the most of market opportunities and grow value from our products over the medium term.”
New Zealand currently produces around 1500 tonnes of blood plasma per annum of which 99 percent is exported for use in the manufacture of medical pharmaceuticals and nutritional products. The investment also aligns with the Ministry of Business Innovation & Employment’s Business Growth Agenda themes of encouraging innovation with clear links to export markets.